- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on May 21, 2013
b3c newswire
>6th Monolith Summer School & Symposium to be held on May 30th - June 4th, 2014, Slovenia
>Biotage and Peptide Synthesis
>Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
>6th Monolith Summer School & Symposium to be held on May 30th - June 4th, 2014, Slovenia
>Biotage and Peptide Synthesis
>Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
BioSpace
>There are a Zillion Biotech Conferences. Which Should You Attend?
>Actavis Nabs Warner Chilcott, PLC for $8.5 Billion
>Coffee Lowers Risk of Rare Liver Disease, Mayo Clinic Study
>Elan Corporation PLC Spends $380 Million to Repel Royalty Pharma Bid, Eyes More Deals With $1 Billion Warchest
>Vitamin D May Treat Asthma, King's College London Study
>There are a Zillion Biotech Conferences. Which Should You Attend?
>Actavis Nabs Warner Chilcott, PLC for $8.5 Billion
>Coffee Lowers Risk of Rare Liver Disease, Mayo Clinic Study
>Elan Corporation PLC Spends $380 Million to Repel Royalty Pharma Bid, Eyes More Deals With $1 Billion Warchest
>Vitamin D May Treat Asthma, King's College London Study
BioSpace - Breaking News
>"Love Hormone" Promises Safer Births After Pfizer Inc. Flop
>Health Canada: Three Companies Recall Antipsychotic Drug Quetiapine
>Former Merck & Co., Inc. Pipefitter Files Civil Rights Lawsuit Against Company
>Serbia Arrests Eight Over Embezzlement
>Veloxis Pharmaceuticals A/S Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors
>"Love Hormone" Promises Safer Births After Pfizer Inc. Flop
>Health Canada: Three Companies Recall Antipsychotic Drug Quetiapine
>Former Merck & Co., Inc. Pipefitter Files Civil Rights Lawsuit Against Company
>Serbia Arrests Eight Over Embezzlement
>Veloxis Pharmaceuticals A/S Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors
Biotech News - Business Wire
>Verastem to Present at Upcoming Conferences
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
>Covidien's Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest Physicians
>OncoSec Medical to Present at the Second Annual Marcum LLP MicroCap Conference
>Verastem to Present at Upcoming Conferences
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
>Covidien's Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest Physicians
>OncoSec Medical to Present at the Second Annual Marcum LLP MicroCap Conference
Biotech News - PR Newswire
>Complix to Present at Upcoming BioEquity Europe 2013
>Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
>MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
>Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system
>GenoVive, ein Pionier im Bereich der DNA-basierten Gewichtsabnahmelösungen, gab heute den Beginn seiner ersten europäischen Partnerschaft mit dem polnischen Unternehmen DNADIETA am 1. Mai 2013 bekannt.
>Complix to Present at Upcoming BioEquity Europe 2013
>Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
>MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
>Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system
>GenoVive, ein Pionier im Bereich der DNA-basierten Gewichtsabnahmelösungen, gab heute den Beginn seiner ersten europäischen Partnerschaft mit dem polnischen Unternehmen DNADIETA am 1. Mai 2013 bekannt.
Biotechnology - Moreover
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
Burrill Report
>Obama Administration Offers $1 Billion for Healthcare Innovation
>Pharma to Support Early-Stage Biotechs
>Scientists Report Human Stem Cell Cloning Success
>Supreme Court Rules Unanimously in Favor of Monsanto
>Saving Normal
>Obama Administration Offers $1 Billion for Healthcare Innovation
>Pharma to Support Early-Stage Biotechs
>Scientists Report Human Stem Cell Cloning Success
>Supreme Court Rules Unanimously in Favor of Monsanto
>Saving Normal
CenterWatch - Clinical Trials
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
Clinical Trials - Business Wire
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
Clinical Trials - PR Newswire
>Verrata? Pressure Guide Wire and iFR® (Instant Wave-Free Ratio?) Software Modality will be on display at EuroPCR 2013[1]
>Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report
>New Study Identifies the Optimal Dose of Intravenous Vitamin C for Future Anticancer Clinical Trials
>The WIRB-Copernicus Group Partners with Mytrus, Inc. to Deliver Revolutionary, Interactive Electronic Informed Consent Solution
>CardioDx Announces Publication of the IMPACT-CARD Trial Demonstrating Use of Corus® CAD Test Influenced Cardiologists' Clinical Management of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease
>Verrata? Pressure Guide Wire and iFR® (Instant Wave-Free Ratio?) Software Modality will be on display at EuroPCR 2013[1]
>Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report
>New Study Identifies the Optimal Dose of Intravenous Vitamin C for Future Anticancer Clinical Trials
>The WIRB-Copernicus Group Partners with Mytrus, Inc. to Deliver Revolutionary, Interactive Electronic Informed Consent Solution
>CardioDx Announces Publication of the IMPACT-CARD Trial Demonstrating Use of Corus® CAD Test Influenced Cardiologists' Clinical Management of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease
CNN Top Stories
>The Doors' Ray Manzarek dies
>Official expecting 40 more bodies
>Stop the hate on Twitter
>Kepler or not, we'll find life
>What happened to Obama's promise?
>The Doors' Ray Manzarek dies
>Official expecting 40 more bodies
>Stop the hate on Twitter
>Kepler or not, we'll find life
>What happened to Obama's promise?
Contract Pharma
>Actavis to Acquire Warner Chilcott
>Sparta Systems Launches TrackWise Analytics
>Aridis Acquires Kenta mAb Portfolio
>AbbVie, Galapagos Extend Collaboration
>QPharma Appoints Medical Officer
>Actavis to Acquire Warner Chilcott
>Sparta Systems Launches TrackWise Analytics
>Aridis Acquires Kenta mAb Portfolio
>AbbVie, Galapagos Extend Collaboration
>QPharma Appoints Medical Officer
FDA Drugs- What's New
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
FDA News - Business Wire
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>Biogen Idec Submits Application to FDA for Approval of PLEGRIDY? (Peginterferon Beta-1a) in Multiple Sclerosis
>Biogen Idec presenta all'FDA una domanda di approvazione per il PLEGRIDY? (Peginterferone Beta-1a) per la sclerosi multipla
>Biogen Idec soumet une demande auprès de la FDA pour l'approbation du PLEGRIDY? (peginterféron bêta-1a) contre la sclérose en plaques
>Biogen Idec reicht Zulassungsantrag für PLEGRIDY? (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>Biogen Idec Submits Application to FDA for Approval of PLEGRIDY? (Peginterferon Beta-1a) in Multiple Sclerosis
>Biogen Idec presenta all'FDA una domanda di approvazione per il PLEGRIDY? (Peginterferone Beta-1a) per la sclerosi multipla
>Biogen Idec soumet une demande auprès de la FDA pour l'approbation du PLEGRIDY? (peginterféron bêta-1a) contre la sclérose en plaques
>Biogen Idec reicht Zulassungsantrag für PLEGRIDY? (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein
FDA Press Releases
>FDA expands alert to health care providers about lack of sterility assurance of all sterile drug products from NuVision Pharmacy
>FDA seeks preliminary injunction against New York fish manufacturer
>FDA approves Simponi to treat ulcerative colitis
>FDA approves new drug for advanced prostate cancer
>FDA approves Nymalize--first nimodipine oral solution for use in certain brain hemorrhage patients
>FDA expands alert to health care providers about lack of sterility assurance of all sterile drug products from NuVision Pharmacy
>FDA seeks preliminary injunction against New York fish manufacturer
>FDA approves Simponi to treat ulcerative colitis
>FDA approves new drug for advanced prostate cancer
>FDA approves Nymalize--first nimodipine oral solution for use in certain brain hemorrhage patients
FDA Vaccines, Blood and Biologics - What's New
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
>Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
>Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility
FierceBiotech
>Karyopharm grabs $48M round for pipeline work
>FDA bestows 'Breakthrough Therapy' status to drug for fatal infant disease
>Pentagon adviser quietly pocketed biotech's cash while promoting its interests
>FDA: Merck's sleep drug suvorexant effective, but safety issues draw heavy flak
>XenoPort shares skid after MS drug proves to be a lemon in PhIII
>Karyopharm grabs $48M round for pipeline work
>FDA bestows 'Breakthrough Therapy' status to drug for fatal infant disease
>Pentagon adviser quietly pocketed biotech's cash while promoting its interests
>FDA: Merck's sleep drug suvorexant effective, but safety issues draw heavy flak
>XenoPort shares skid after MS drug proves to be a lemon in PhIII
FierceBiotech IT
>Pfizer-backed analysis finds dearth of patient-reported outcomes in trials
>Chinese drug giant tackles drug counterfeiting with mobile service
>InSilico Genomics grabs $1.5M for fledgling bioinformatics biz
>Drugmaker UCB taps IBM for digital medicine effort
>Life sciences VC firm launches 'crowdfunding' site for limited crowd
>Pfizer-backed analysis finds dearth of patient-reported outcomes in trials
>Chinese drug giant tackles drug counterfeiting with mobile service
>InSilico Genomics grabs $1.5M for fledgling bioinformatics biz
>Drugmaker UCB taps IBM for digital medicine effort
>Life sciences VC firm launches 'crowdfunding' site for limited crowd
FierceBiotech Research
>Researchers pinpoint protein involved in cancer cell death
>Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease
>Drug boosts effectiveness of radiation therapy for brain tumors
>Scientists use cloning method to create embryonic stem cells
>Stem cell therapy treats common pregnancy complication
>Researchers pinpoint protein involved in cancer cell death
>Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease
>Drug boosts effectiveness of radiation therapy for brain tumors
>Scientists use cloning method to create embryonic stem cells
>Stem cell therapy treats common pregnancy complication
FiercePharma
>Shire eyes takeover protection as bid rumors swirl, Mail says
>Ex-HGS director draws fire for plugging anthrax drug at Pentagon
>Women want Apotex to pay for unwanted pregnancies
>GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
>JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets
>Shire eyes takeover protection as bid rumors swirl, Mail says
>Ex-HGS director draws fire for plugging anthrax drug at Pentagon
>Women want Apotex to pay for unwanted pregnancies
>GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
>JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets
FiercePharma Manufacturing
>Apotex sued over problems on contraceptive packaging line
>China arrests dozens, seizes tens of millions of counterfeit drugs
>Worker hurt in 'flash fire' at Amgen facility
>CEO of J&J OTC unit in Korea faces criminal action over plant foul-up
>Recalls jump 32% in first quarter
>Apotex sued over problems on contraceptive packaging line
>China arrests dozens, seizes tens of millions of counterfeit drugs
>Worker hurt in 'flash fire' at Amgen facility
>CEO of J&J OTC unit in Korea faces criminal action over plant foul-up
>Recalls jump 32% in first quarter
FierceVaccines
>Taliban drops campaign against polio vaccine
>Human-to-human coronavirus spread looks likely
>Novartis taps synthetic biology to speed vax development
>Indian rotavirus vax set to undercut GSK and Merck
>Media reports used to track global vaccine backlash
>Taliban drops campaign against polio vaccine
>Human-to-human coronavirus spread looks likely
>Novartis taps synthetic biology to speed vax development
>Indian rotavirus vax set to undercut GSK and Merck
>Media reports used to track global vaccine backlash
Health News - BizJournals.com
>Dynamics launches LifeCode; expands beyond payment cards
>Gateway Rehab CEO gets lifetime achievement award
>Florida Hospital Waterman CEO swaps jobs with Flagler hospital exec
>UPMC to lay off transcription workers
>360 Vantage acquired by IMS Health
>Dynamics launches LifeCode; expands beyond payment cards
>Gateway Rehab CEO gets lifetime achievement award
>Florida Hospital Waterman CEO swaps jobs with Flagler hospital exec
>UPMC to lay off transcription workers
>360 Vantage acquired by IMS Health
Health News - CNBC
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
Health News - Fox Business
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
Inside Industry - Gen
>Collaboration Aims to Create In Vitro Human Skin
>Actavis Acquiring Warner Chilcott for $8.5B
>Amgen Forms Joint Venture to Sell Vectibix in China
>FDA OKs Novartis' Childhood Arthritis Drug
>ATMI Supplies Bioreactor for Orgenesis, Takes $1.3M Stake
>Collaboration Aims to Create In Vitro Human Skin
>Actavis Acquiring Warner Chilcott for $8.5B
>Amgen Forms Joint Venture to Sell Vectibix in China
>FDA OKs Novartis' Childhood Arthritis Drug
>ATMI Supplies Bioreactor for Orgenesis, Takes $1.3M Stake
Marketwire - Pharma and Biotech
>YFRM Technologies, Inc. Completes Acquisition of the Integrative Stem Cell Institute
>CampDoc.com Releases Electronic Medication Administration Record for Summer Camps
>Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441
>The 14th Annual BioEquity Europe Conference Features 96 Innovator Companies With Differentiated Products, Upcoming Milestones and Partner-Ready Assets
>Taconic promueve a David T. Hansen para liderar el crecimiento de modelos y servicios de ingenier?gen?ca para investigaci?
>YFRM Technologies, Inc. Completes Acquisition of the Integrative Stem Cell Institute
>CampDoc.com Releases Electronic Medication Administration Record for Summer Camps
>Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441
>The 14th Annual BioEquity Europe Conference Features 96 Innovator Companies With Differentiated Products, Upcoming Milestones and Partner-Ready Assets
>Taconic promueve a David T. Hansen para liderar el crecimiento de modelos y servicios de ingenier?gen?ca para investigaci?
MassBio News
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
Medical Pharma - PR Newswire
>La encuesta mundial más grande que se haya realizado a 1,273 mujeres de 12 países revela que las mujeres con cáncer de mama avanzado se sienten excluidas del movimiento de lucha contra el cáncer mama
>Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement
>Glenn Close Narrates Groundbreaking New Documentary That Shatters Misconceptions About Mental Illness
>Net Health Acquires Integritas, Urgent Care and Occupational Health Leader
>BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
>La encuesta mundial más grande que se haya realizado a 1,273 mujeres de 12 países revela que las mujeres con cáncer de mama avanzado se sienten excluidas del movimiento de lucha contra el cáncer mama
>Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement
>Glenn Close Narrates Groundbreaking New Documentary That Shatters Misconceptions About Mental Illness
>Net Health Acquires Integritas, Urgent Care and Occupational Health Leader
>BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
National Center for Biotechnology Information
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
Nature Biotechnology
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
>Footrace to clinic heats up for T-cell nuclear receptor inhibitors
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
>Footrace to clinic heats up for T-cell nuclear receptor inhibitors
New York Times- Biotechnology
>Building a $325,000 Burger
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
>Don’t Be Afraid of Genetic Modification
>Improper Efforts to Limit Competitive Drugs
>Building a $325,000 Burger
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
>Don’t Be Afraid of Genetic Modification
>Improper Efforts to Limit Competitive Drugs
New York Times- Pharmaceuticals
>Pills Tracked From Doctor to Patient to Aid Drug Marketing
>Melanoma Treatment Harnesses Immune System to Combat Cancer Cells
>Estimated Health Costs in Retirement Drop
>Generic Drug Maker Pleads Guilty in Federal Case
>Doctors' Lucrative Industry Ties
>Pills Tracked From Doctor to Patient to Aid Drug Marketing
>Melanoma Treatment Harnesses Immune System to Combat Cancer Cells
>Estimated Health Costs in Retirement Drop
>Generic Drug Maker Pleads Guilty in Federal Case
>Doctors' Lucrative Industry Ties
OnBioVC
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
Outsourcing-Pharma
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
Pharma News - Business Wire
>Verastem to Present at Upcoming Conferences
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
>Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin?
>Research and Markets: Osteoarthritis Partnering 2007-2013
>Verastem to Present at Upcoming Conferences
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
>Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin?
>Research and Markets: Osteoarthritis Partnering 2007-2013
Pharma News - PharmiWeb
>ClinTec International expands further in MENA region with proposed opening of Istanbul Office
>Padma Bhushan Dr. Nandkishore Shamrao Laud to receive Lifetime Achievement Award at India Leadership Conclave 2013
>Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report
>CML Drug Revenue in Japan to Grow, Despite Global Decline
>Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices
>ClinTec International expands further in MENA region with proposed opening of Istanbul Office
>Padma Bhushan Dr. Nandkishore Shamrao Laud to receive Lifetime Achievement Award at India Leadership Conclave 2013
>Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report
>CML Drug Revenue in Japan to Grow, Despite Global Decline
>Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices
Pharma News - PR Newswire
>Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
>Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
>Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study
>RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care
>Gemeinsamer Bundesausschuss (G-BA) gibt Beschluss über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V für Pixantron (Pixuvri®) bekannt.
>Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
>Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
>Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study
>RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care
>Gemeinsamer Bundesausschuss (G-BA) gibt Beschluss über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V für Pixantron (Pixuvri®) bekannt.
Pharmaceutical - Moreover
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
PR Leap - Biotech
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
PRWeb - Biotechnology
>Possible Mold Re-infestation Gets Guilmette School Scheduled for...
>Vital Imaging Makes Greater Commitment into MRI Research
>Inflamax Research selected by the Immune Tolerance Network and the...
>Nanonex Announces the Shipment and Installation of an Innovative...
>Revolutionary Science Announces New Automatic and Manual Colony...
>Possible Mold Re-infestation Gets Guilmette School Scheduled for...
>Vital Imaging Makes Greater Commitment into MRI Research
>Inflamax Research selected by the Immune Tolerance Network and the...
>Nanonex Announces the Shipment and Installation of an Innovative...
>Revolutionary Science Announces New Automatic and Manual Colony...
PRWeb - Pharmaceuticals
>Global Vision's Text Comparison Software Docu-Proof Recognized by...
>CEO of Execution Management and Strategic Planning Software Company...
>MD Aligne is the Best Choice for Supplemental Healthcare Due to...
>Brooklyn Smiles, the Premier Dentist in Brooklyn, Becomes a Top 100...
>Leading South Florida Pain Clinic, Prime Care, Now Offering Board...
>Global Vision's Text Comparison Software Docu-Proof Recognized by...
>CEO of Execution Management and Strategic Planning Software Company...
>MD Aligne is the Best Choice for Supplemental Healthcare Due to...
>Brooklyn Smiles, the Premier Dentist in Brooklyn, Becomes a Top 100...
>Leading South Florida Pain Clinic, Prime Care, Now Offering Board...
Scientific American
>Why Penguins Cannot Fly
>Drought Gobbles Up Texas Turkey Hunt
>Heat Deaths in New York City Predicted to Rise
>Stress Makes Gorilla Glass Stronger
>Childhood ADHD Linked to Obesity in Adulthood
>Why Penguins Cannot Fly
>Drought Gobbles Up Texas Turkey Hunt
>Heat Deaths in New York City Predicted to Rise
>Stress Makes Gorilla Glass Stronger
>Childhood ADHD Linked to Obesity in Adulthood
Sports - ESPN Basketball
>Freshman Impact: Ohio State
>Ex-Rutgers coach Rice receiving counseling
>Florida Intl. guard Smith transfers to Minnesota
>Black transfers to Kansas, can play right away
>Report: Coach K considering Team USA return
>Freshman Impact: Ohio State
>Ex-Rutgers coach Rice receiving counseling
>Florida Intl. guard Smith transfers to Minnesota
>Black transfers to Kansas, can play right away
>Report: Coach K considering Team USA return
Sports News - ESPN
>100 numbers to know for the 2013 college football season
>QB Lunt mulls Illinois after visit, sources say
>Former Arkansas QB Mitchell picks NC State
>McCartney back on WVU roster after 6 months
>Sources: C-USA to put team in Military Bowl
>100 numbers to know for the 2013 college football season
>QB Lunt mulls Illinois after visit, sources say
>Former Arkansas QB Mitchell picks NC State
>McCartney back on WVU roster after 6 months
>Sources: C-USA to put team in Military Bowl
Xconomy Life Sciences
>Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs
>NanoString Technologies Maneuvers In Line for $86M IPO
>Accelerate LI's Lofty Goal: Create the Next U.S. Innovation Cluster
>Zillions of Biotech Conferences Want You. Which Should You Attend?
>XBiotech Takes Aim at Inflammation That Weakens Cancer Patients
>Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs
>NanoString Technologies Maneuvers In Line for $86M IPO
>Accelerate LI's Lofty Goal: Create the Next U.S. Innovation Cluster
>Zillions of Biotech Conferences Want You. Which Should You Attend?
>XBiotech Takes Aim at Inflammation That Weakens Cancer Patients
Yahoo Biotech News
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)